Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

75 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Gumarontinib in patients with non-small-cell lung cancer harbouring MET exon 14 skipping mutations: a multicentre, single-arm, open-label, phase 1b/2 trial.
Yu Y, Zhou J, Li X, Goto K, Min X, Nishino K, Cui J, Wu L, Sakakibara J, Shu Y, Dong X, Li L, Yoneshima Y, Zhou C, Li X, Zhang Y, Huang D, Zang A, Zhang W, Wang X, Zhang L, Bai C, Fang J, Cao L, Zhao Y, Yu Y, Shi M, Zhong D, Li F, Li M, Wu Q, Zhou J, Sun M, Lu S. Yu Y, et al. Among authors: yoneshima y. EClinicalMedicine. 2023 Apr 6;59:101952. doi: 10.1016/j.eclinm.2023.101952. eCollection 2023 May. EClinicalMedicine. 2023. PMID: 37096188 Free PMC article.
Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study.
Kenmotsu H, Wakuda K, Mori K, Kato T, Sugawara S, Kirita K, Yoneshima Y, Azuma K, Nishino K, Teraoka S, Shukuya T, Masuda K, Hayashi H, Toyozawa R, Miura S, Fujimoto D, Nakagawa K, Yamamoto N, Takahashi T. Kenmotsu H, et al. Among authors: yoneshima y. J Thorac Oncol. 2022 Sep;17(9):1098-1108. doi: 10.1016/j.jtho.2022.05.006. Epub 2022 May 27. J Thorac Oncol. 2022. PMID: 35636696 Free article. Clinical Trial.
Carboplatin and irinotecan (CI) vs. carboplatin and etoposide (CE) for the treatment of extended-stage small-cell lung cancer in an elderly population: A phase II/III randomized control trial.
Shimokawa T, Okamoto H, Machida R, Misumi Y, Hosomi Y, Yoneshima Y, Tanaka H, Okishio K, Simizu J, Goto K, Akamatsu H, Kubota K, Nakagawa K, Horinouchi H, Ando M, Kataoka T, Ohe Y. Shimokawa T, et al. Among authors: yoneshima y. Lung Cancer. 2023 Jul;181:107195. doi: 10.1016/j.lungcan.2023.107195. Epub 2023 Apr 22. Lung Cancer. 2023. PMID: 37156212 Free article. Clinical Trial.
Final Analysis Data and Exploratory Biomarker Analysis of a Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib Monotherapy for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: The WJOG9717L Study.
Kenmotsu H, Sakai K, Mori K, Kato T, Sugawara S, Kirita K, Yoneshima Y, Azuma K, Nishino K, Teraoka S, Koyama R, Masuda K, Hayashi H, Toyozawa R, Miura S, Sato Y, Nakagawa K, Yamamoto N, Nishio K, Takahashi T. Kenmotsu H, et al. Among authors: yoneshima y. JTO Clin Res Rep. 2024 Aug 23;5(11):100716. doi: 10.1016/j.jtocrr.2024.100716. eCollection 2024 Nov. JTO Clin Res Rep. 2024. PMID: 39399795 Free PMC article.
Regulation of PD-L1 expression in non-small cell lung cancer by interleukin-1β.
Hirayama A, Tanaka K, Tsutsumi H, Nakanishi T, Yamashita S, Mizusaki S, Ishii Y, Ota K, Yoneshima Y, Iwama E, Okamoto I. Hirayama A, et al. Among authors: yoneshima y. Front Immunol. 2023 Jun 27;14:1192861. doi: 10.3389/fimmu.2023.1192861. eCollection 2023. Front Immunol. 2023. PMID: 37441079 Free PMC article.
75 results